Clinical Trial

A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study will evaluate the safety and efficacy of a new antimalarial drug GSK3772701 (a pyrrolidinamide), using different doses and treatment durations, in adult participants with uncomplicated Plasmodium (P.) falciparum malaria.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-16.
Trial Details
NCT Number NCT07545681
Lead Sponsor GlaxoSmithKline
Conditions Malaria, Falciparum
Enrollment 70 participants
Start Date 2026-07-28
Primary Completion 2027-07-29 (estimated)
Study Completion 2027-07-29 (estimated)
Updated on ClinicalTrials.gov 2026-07-08